The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer(275 views) Danforth Dn JR, Aloj L, Carrasquillo JA, Bacharach SL, Chow C, Zujewski J, Whatley M, Galen B, Merino M, Neumann RD
Breast Cancer Res Tr Kluwer Academic Publishers (ISSN: 0167-6806), 2002; 75(2): 135-146.
Keywords: 18f-Fluorodeoxyglucose, Breast Cancer, Imaging, Local Regional Tumor, Monitoring Response To Chemotherapy, Positron Emission Tomography, Staging, Antineoplastic Agent, Fluorodeoxyglucose F 18, Diagnostic Agent, Fluorine, Adult, Article, Axillary Lymph Node, Cancer Adjuvant Therapy, Cancer Diagnosis, Cancer Staging, Clinical Article, Controlled Study, Diagnostic Procedure, Female, Human, Kin Selection, Lymph Node Metastasis, Postmenopause, Premenopause, Priority Journal, Breast Tumor, Computer Assisted Emission Tomography, Glucose Blood Level, Metabolism, Methodology, Middle Aged, Pathology, Scintiscanning, Whole Body Counting, Blood Glucose, Breast Neoplasms, Fluorine Radioisotopes, Lymphatic Metastasis, Neoplasm Staging, Emission-Computed, Whole-Body Counting,
Affiliations: *** IBB - CNR ***
Surgery Branch, National Cancer Institute, Bethesda, MD, United States
Nuclear Medicine Dept., Bethesda, MD, United States
Diagnostic Radiology Department, Clinical Center, National Institutes of Health, Bethesda, MD, United States
Medicine Branch, Bethesda, MD, United States
Laboratory of Pathology, National Cancer Institute, Bethesda, MD, United States
References: Greenlee, R.T., Murray, T., Bolden, S., Wingo, P.A., Cancer Statistics 2000 (2000) CA: A Cancer J Clinicians, 50, pp. 7-3
Hata, Y., Ogawa, Y., Nishioka, A., Inomata, T., Yoshida, S., Thin section computed tomography in the prone position for detection of axillary lymph node metastases in breast cancer (1998) Oncol Rep, 5, pp. 1403-1406
Lernevall, A., Imaging of axillary lymph nodes (2000) Acta Oncol, 39, pp. 277-281
Warburg, O., (1931) The Metabolism of Tumors, , Richard R. Smith, Inc
Gallagher, B.M., Fowler, J.S., Gutterson, N.I., MacGregor, R.R., Wan, C.N., Wolf, A.P., Metabolic trapping as a principle of oradiopharmaceutical design: Some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose (1978) J Nucl Med, 19, pp. 1154-1161
Adler, L.P., Crowe, J.P., Al-Kaisi, N.K., Sunshine, J.L., Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET (1993) Radiol, 187, pp. 743-750
Tse, N.Y., Hoh, C.K., Hawkins, R.A., Zinner, M.J., Dahlbom, M., Choi, Y., Maddahi, J., Glaspy, J.A., The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease (1992) Ann Surg, 216, pp. 27-34
Scheidhauer, K., Scharl, A., Pietrzyk, U., Qualitative {18F} FDG positron emission tomography (1996) Eur J Nucl Med, 6, pp. 618-623
Dehdashti, F., Mortimer, J.E., Siegel, B.A., Griffeth, L.K., Bonasera, T.J., Fusselman, M.J., Detert, D.D., Welch, M.J., Positron tomographic assessment of estrogen receptors in breast cancer: Comparison with FDG-PET and in vitro receptor assays (1995) J Nucl Med, 36, pp. 1766-1774
Bassa, P., Inoue, T., Wong, F.C., Korkmaz, M., Yang, D.J., Wong, W.H., Hicks, K.W., Podoloff, D.A., Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer (1996) J Nucl Med, 37, pp. 931-938
Avril, N., Menzel, M., Dose, J., Schelling, M., Weber, W., Janicke, F., Nathrath, W., Schwaiger, M., Glucose metabolism of breast cancer assessed by 18F-FDG PET: Histologic and immunohistochemical tissue analysis (2001) J Nucl Med, 42, pp. 9-16
Avril, N., Dose, J., Janicke, F., Ziegler, S., Romer, W., Weber, W., Herz, M., Schwaiger, M., Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(Fluorine-18)-fluoro-2-deoxy-D-glucose (1996) JNCI, 88, pp. 1204-1209
Noh, D.Y., Yun, I.J., Kim, J.S., Kang, H.S., Lee, D.S., Chung, J.K., Lee, M.C., Choe, K.J., Diagnostic value of positron emission tomography for detecting breast cancer (1998) World J Surg, 22, pp. 223-228
Adler, L.P., Faulhaber, P.F., Schnur, K.C., Al-Kasi, N.L., Shenk, R.R., Axillary lymph node metastases: Screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET (1997) Radiol, 203, pp. 323-327
Cook, G.J., Houston, S., Maisey, M.N., Fogelman, I., Detection of bone metastases in breast cancer by 18FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesions (1998) J Clin Oncol, 16, pp. 3375-3379
Petren-Mallmin, M., Andreasson, I., Ljunggren, O., Ahlstrom, H., Bergh, J., Antoni, G., Langstrom, B., Bergstrom, M., Skeletal metastases from breast cancer: Uptake of 18F-fluoride measured with positron emission tomography in correlation with CT (1998) Skel Radiol, 27, pp. 72-76
Bender, H., Kirst, J., Palmedo, H., Schomburg, A., Wagner, U., Ruhlmann, J., Biersack, H.J., Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma (1997) Anticancer Res, 17, pp. 1687-1692
Jansson, T., Westlin, J.E., Ahlstrom, H., Langstrom, B., Bergh, J., Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation (1995) J Clin Oncol, 13, pp. 1470-1477
Wahl, R.L., Zasadny, K., Helvie, M., Hutchins, G.D., Weber, B., Cody, R., Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation (1993) J Clin Oncol, 11, pp. 2101-2111
Schelling, M., Avril, N., Nahrig, J., Kuhn, W., Romer, W., Sattler, D., Werner, M., Schwaiger, M., Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer (2000) J Clin Oncol, 18, pp. 1689-1695
Smith, I.C., Welch, A.E., Hutcheon, A.W., Miller, I.D., Payne, S., Chilcott, F., Waikar, S., Sharp, P.F., Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy (2000) J Clin Oncol, 18, pp. 1676-1688
Oshida, M., Uno, K., Suzuki, M., Nagashima, T., Hashimoto, H., Yageta, H., Shishikura, T., Nakajima, N., Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose (1998) Cancer, 82, pp. 2227-2234
Crippa, F., Seregni, E., Agresti, R., Chiesa, C., Pascali, C., Bogni, A., Decise, D., Bombardieri, E., Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: A preliminary observation (1998) Eur J Nucl Med, 25, pp. 1429-1434
Eubank, W.B., Mankoff, D.A., Takasugi, J., Vesselle, H., Eary, J.F., Shanley, T.J., Gralow, J.R., Livingston, R.B., 18Fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer (2001) J Clin Oncol, 19, pp. 3516-3523
(1978) Breast cancer: Suggested protocol guidelines for combination chemotherapy trials and for combined modality trials, , Washington, DC United States Department of Health, Education, and Welfare Publication 78-1192
Smith, I.C., Ogston, K.N., Whitford, P., Smith, F.W., Sharp, P., Norton, M., Miller, I.D., Eremin, O., Staging of the axilla in breast cancer (1998) Ann Surg, 228, pp. 220-227
Edge, S.B., Hurd, T.C., Sentinel lymph node update: Breast cancer (2001) Oncology, 13, pp. 213-218
Yang, J.H., Nam, S.J., Lee, T.S., Lee, H.K., Jung, S.H., Kim, B.T., Comparison of intraoperative frozen section analysis of sentinel node with preoperative positron emission tomography in the diagnosis of axillary lymph node status in breast cancer patients (2001) Jpn J Clin Oncol, 31, pp. 1-6
Danforth, D.N., Zujewski, J., O'Shaughnessy, J., Riseberg, D., Steinberg, D., Steinberg, S.M., McAtee, N., Cowan, K.H., Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA,B breast cancer (1998) Ann Surg Oncol, 5, pp. 150-158
Julian, T.B., Patel, N., Dusi, D., Olson, P., Nathan, G., Jasnosz, K., Isaacs, G., Wolmark, N., Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer (2001) Am J Surg, 182, pp. 407-410
Haid, A., Tausch, C., Lang, A., Lutz, J., Fritzsche, H., Peschina, W., Breitfellner, G., Zimmermann, G., Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast carcinoma? (2001) Cancer, 92, pp. 1080-1084
Nason, K.S., Anderson, B.O., Byrd, D.R., Dunnwald, L.K., Eary, J.F., Mankoff, D.A., Livingston, R., Moe, R.E., Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma (2000) Cancer, 89, pp. 2187-2194
Greenlee, R. T., Murray, T., Bolden, S., Wingo, P. A., Cancer Statistics 2000 (2000) CA: A Cancer J Clinicians, 50, pp. 7-3
Gallagher, B. M., Fowler, J. S., Gutterson, N. I., MacGregor, R. R., Wan, C. N., Wolf, A. P., Metabolic trapping as a principle of oradiopharmaceutical design: Some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose (1978) J Nucl Med, 19, pp. 1154-1161
Adler, L. P., Crowe, J. P., Al-Kaisi, N. K., Sunshine, J. L., Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET (1993) Radiol, 187, pp. 743-750
Tse, N. Y., Hoh, C. K., Hawkins, R. A., Zinner, M. J., Dahlbom, M., Choi, Y., Maddahi, J., Glaspy, J. A., The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease (1992) Ann Surg, 216, pp. 27-34
Noh, D. Y., Yun, I. J., Kim, J. S., Kang, H. S., Lee, D. S., Chung, J. K., Lee, M. C., Choe, K. J., Diagnostic value of positron emission tomography for detecting breast cancer (1998) World J Surg, 22, pp. 223-228
Adler, L. P., Faulhaber, P. F., Schnur, K. C., Al-Kasi, N. L., Shenk, R. R., Axillary lymph node metastases: Screening with [F-18] 2-deoxy-2-fluoro-D-glucose (FDG) PET (1997) Radiol, 203, pp. 323-327
Cook, G. J., Houston, S., Maisey, M. N., Fogelman, I., Detection of bone metastases in breast cancer by 18FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesions (1998) J Clin Oncol, 16, pp. 3375-3379
Wahl, R. L., Zasadny, K., Helvie, M., Hutchins, G. D., Weber, B., Cody, R., Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation (1993) J Clin Oncol, 11, pp. 2101-2111
Smith, I. C., Welch, A. E., Hutcheon, A. W., Miller, I. D., Payne, S., Chilcott, F., Waikar, S., Sharp, P. F., Positron emission tomography using [(18) F] -fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy (2000) J Clin Oncol, 18, pp. 1676-1688
Eubank, W. B., Mankoff, D. A., Takasugi, J., Vesselle, H., Eary, J. F., Shanley, T. J., Gralow, J. R., Livingston, R. B., 18Fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer (2001) J Clin Oncol, 19, pp. 3516-3523
(1978) Breast cancer: Suggested protocol guidelines for combination chemotherapy trials and for combined modality trials, , Washington, DC United States Department of Health, Education, and Welfare Publication 78-1192
Smith, I. C., Ogston, K. N., Whitford, P., Smith, F. W., Sharp, P., Norton, M., Miller, I. D., Eremin, O., Staging of the axilla in breast cancer (1998) Ann Surg, 228, pp. 220-227
Edge, S. B., Hurd, T. C., Sentinel lymph node update: Breast cancer (2001) Oncology, 13, pp. 213-218
Yang, J. H., Nam, S. J., Lee, T. S., Lee, H. K., Jung, S. H., Kim, B. T., Comparison of intraoperative frozen section analysis of sentinel node with preoperative positron emission tomography in the diagnosis of axillary lymph node status in breast cancer patients (2001) Jpn J Clin Oncol, 31, pp. 1-6
Danforth, D. N., Zujewski, J., O'Shaughnessy, J., Riseberg, D., Steinberg, D., Steinberg, S. M., McAtee, N., Cowan, K. H., Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA, B breast cancer (1998) Ann Surg Oncol, 5, pp. 150-158
Julian, T. B., Patel, N., Dusi, D., Olson, P., Nathan, G., Jasnosz, K., Isaacs, G., Wolmark, N., Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer (2001) Am J Surg, 182, pp. 407-410
Nason, K. S., Anderson, B. O., Byrd, D. R., Dunnwald, L. K., Eary, J. F., Mankoff, D. A., Livingston, R., Moe, R. E., Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma (2000) Cancer, 89, pp. 2187-2194
The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer
Purpose. In women with breast cancer, knowledge of the local/regional extent of the tumor is essential for staging, treatment planning, monitoring response to therapy, and follow-up. Positron emission tomography (PET) is an important imaging test which can detect tumor at multiple sites in women with breast cancer. We compared the ability of PET to provide a comprehensive view of the local/regional extent of tumor in women with stage I, II and stage III, IV breast cancer. Materials and methods. Forty-six women with breast cancer underwent PET using 18F-FDG. 18FDG uptake in the breast primary tumor, associated skin, axillary and internal mammary lymph nodes, and the contralateral breast was determined qualitatively, and correlated with histologic, clinical and radiographic findings. Results. Twenty-four patients were premenopausal and 22 were postmenopausal, with the following distribution according to clinical stage: stage I - 2 patients, stage II - 16, stage III - 16, stage IV - 12 patients. Among stage I, II patients, the sensitivity for detection of the primary tumor was 83.3%, and for detection of axillary lymph node metastases was 42.9%. 18FDG-PET was negative for the breast skin, contralateral breast, and internal mammary lymph nodes in all stage I, II patients, in agreement with clinical and radiographic findings. Among 28 stage III, IV patients, the sensitivity of 18FDG-PET for detection of the primary tumor was 90.5%, and for detection of axillary lymph node metastases 83.3%. Fourteen patients had clinically advanced changes in the skin, and the sensitivity of PET for detection of skin changes was 76.9%. 18FDG-PET was positive in the internal mammary lymph nodes in 25.0%, and negative in the contralateral breast in all patients with stage III, IV breast cancer. 18FDG-PET was studied in 10 patients following neoadjuvant chemotherapy, and showed a strong correlation with clinical response, and with clinical and pathological findings post-treatment at multiple local/regional sites. Conclusion. 18FDG-PET can provide a comprehensive image of local/regional tumor in women with breast cancer. 18FDG-PET may play a greater role in women with stage III, IV breast cancer because of increased sensitivity and the increased involvement of multiple local/regional sites with tumor.
The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer
Cusanno F, Cisbani E, Colilli S, Fratoni R, Garibaldi F, Giuliani F, Gricia M, Lucentini M, Magliozzi ML, Santarivenere F, Torrioli S, Cinti MN, Pani R, Pellegrini R, Simonetti G, Schillaci O, Del Vecchio S, Salvatore M, Majewski S, De Vincentis G, Scopinaro F * Results of clinical trials with SPEM(278 views) Nucl Instrum Methods Phys Res Sect A, 2007 Feb 1; 497(1): 46-50. Impact Factor:3.221 ViewExport to BibTeXExport to EndNote
Hesse B, Tagil K, Cuocolo A, Anagnostopoulos C, Bardies M, Bax J, Bengel F, Busemann Sokole E, Davies G, Dondi M, Edenbrandt L, Franken P, Kjaer A, Knuuti J, Lassmann M, Ljungberg M, Marcassa C, Marie PY, Mckiddie F, O'connor M, Prvuolovich E, Underwood R * 3. 0 T perfusion MR imaging(694 views) Rivista Di Neuroradiologia (ISSN: 1120-9976), 2004; 17(6): 807-812. Impact Factor:0.023 ViewExport to BibTeXExport to EndNote